Quality of life should be the primary outcome for disease-modifying therapy trials in MS—Yes

Yael Goverover; Nancy Chiaravalloti

doi:10.1177/13524585231182705

Quality of life should be the primary outcome for disease-modifying therapy trials in MS—Yes

Yael Goverover, Nancy Chiaravalloti

Occupational Therapy

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1064-1065
Number of pages	2
Journal	Multiple Sclerosis Journal
Volume	29
Issue number	9
DOIs	https://doi.org/10.1177/13524585231182705
State	Published - Aug 2023

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1177/13524585231182705

Cite this

@article{3d0d64bc2f05470398674af39aa92986,

title = "Quality of life should be the primary outcome for disease-modifying therapy trials in MS—Yes",

author = "Yael Goverover and Nancy Chiaravalloti",

year = "2023",

month = aug,

doi = "10.1177/13524585231182705",

language = "English (US)",

volume = "29",

pages = "1064--1065",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "9",

}

TY - JOUR

T1 - Quality of life should be the primary outcome for disease-modifying therapy trials in MS—Yes

AU - Goverover, Yael

AU - Chiaravalloti, Nancy

PY - 2023/8

Y1 - 2023/8

UR - http://www.scopus.com/inward/record.url?scp=85165875352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85165875352&partnerID=8YFLogxK

U2 - 10.1177/13524585231182705

DO - 10.1177/13524585231182705

M3 - Comment/debate

C2 - 37489563

AN - SCOPUS:85165875352

SN - 1352-4585

VL - 29

SP - 1064

EP - 1065

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 9

ER -

Quality of life should be the primary outcome for disease-modifying therapy trials in MS—Yes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this